Matches in Wikidata for { <http://www.wikidata.org/entity/Q92719250> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- Q92719250 description "artículu científicu espublizáu n'agostu de 2019" @default.
- Q92719250 description "scientific article published on 23 August 2019" @default.
- Q92719250 description "wetenschappelijk artikel" @default.
- Q92719250 description "наукова стаття, опублікована 23 серпня 2019" @default.
- Q92719250 name "Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection" @default.
- Q92719250 name "Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection" @default.
- Q92719250 type Item @default.
- Q92719250 label "Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection" @default.
- Q92719250 label "Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection" @default.
- Q92719250 prefLabel "Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection" @default.
- Q92719250 prefLabel "Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection" @default.
- Q92719250 P1433 Q92719250-8BBE5031-2307-4012-AC40-4A09EA8E30A2 @default.
- Q92719250 P1476 Q92719250-B6F8D8D2-02A9-434D-8F3A-F61F3BED3611 @default.
- Q92719250 P2860 Q92719250-027D8A67-5B2B-489B-A88B-B0FFFFED97FC @default.
- Q92719250 P2860 Q92719250-230BB3BE-AD44-4917-9705-04B9E5A0565F @default.
- Q92719250 P2860 Q92719250-3C2B7864-7FE6-495A-BA5E-2A1CDEA4E2EF @default.
- Q92719250 P2860 Q92719250-45D6078E-8BE5-4C86-B1EA-4BF3218A0C7A @default.
- Q92719250 P2860 Q92719250-57EABD12-BF14-495E-A943-A475045B34AC @default.
- Q92719250 P2860 Q92719250-5E984A5F-8604-4DCD-8C44-3578497DFBC9 @default.
- Q92719250 P2860 Q92719250-5F99BE4D-6B60-4549-9824-A9B9D4D5A492 @default.
- Q92719250 P2860 Q92719250-82FBF9E2-B5D4-4613-9519-92E799C97A8C @default.
- Q92719250 P2860 Q92719250-923C337E-51D4-4AC4-B9F9-684FD9CF05CD @default.
- Q92719250 P2860 Q92719250-9FFD1084-2DBC-4F1F-BD45-573A89B1CF18 @default.
- Q92719250 P2860 Q92719250-ADC0A1FA-6EA1-4D8E-8136-970EBAD40271 @default.
- Q92719250 P2860 Q92719250-E3397B13-E8D7-4785-9514-9A5DD02B8180 @default.
- Q92719250 P2860 Q92719250-E3398420-AEAC-4189-82D6-30B2228F5589 @default.
- Q92719250 P2860 Q92719250-E72681A7-8557-496D-BE15-2E0B30004148 @default.
- Q92719250 P2860 Q92719250-EBEEEF56-9043-4C50-A178-86D7CACEE5A6 @default.
- Q92719250 P304 Q92719250-FDE62898-4318-457A-8CC8-56D610594FF4 @default.
- Q92719250 P31 Q92719250-F9C220B3-CD75-47E5-92A7-68A6A6EBE7F6 @default.
- Q92719250 P356 Q92719250-B1CACDBE-99F9-4C5B-8784-C063C49BA88A @default.
- Q92719250 P433 Q92719250-F700ED6D-38C1-4213-9FB4-262CA65E70EE @default.
- Q92719250 P478 Q92719250-A6FA8BD2-86F4-46BC-A287-C24F3B26365A @default.
- Q92719250 P50 Q92719250-210F7550-97FA-4431-8107-2F69F9021139 @default.
- Q92719250 P50 Q92719250-49C9140E-986D-4B4E-8738-1298CAD5EEEF @default.
- Q92719250 P50 Q92719250-4E75DA0C-7CB2-4D0A-B6CF-CB2B53B02D4D @default.
- Q92719250 P50 Q92719250-90875F99-235E-4A1A-B55D-E2684AC1C5CF @default.
- Q92719250 P50 Q92719250-A2DE4D15-804B-4EFE-A172-B2F3C9BD27C7 @default.
- Q92719250 P577 Q92719250-C33152E5-47DD-4BC2-B564-A303E6A50114 @default.
- Q92719250 P698 Q92719250-F61A0ED9-D707-44A7-A54E-8ABB6B11FA4E @default.
- Q92719250 P921 Q92719250-6E9A2BAE-0DD5-4DD8-B457-435E3C7030C4 @default.
- Q92719250 P921 Q92719250-86172F06-5A78-4FC2-8891-8C0B2FEDB0D8 @default.
- Q92719250 P921 Q92719250-C01E8DCA-5980-4EE8-87AF-8AAF53D9419B @default.
- Q92719250 P932 Q92719250-AA914C06-734D-4480-9B17-B99E32D01AFE @default.
- Q92719250 P356 CPT.1543 @default.
- Q92719250 P698 31194885 @default.
- Q92719250 P1433 Q1101529 @default.
- Q92719250 P1476 "Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection" @default.
- Q92719250 P2860 Q24322021 @default.
- Q92719250 P2860 Q26865446 @default.
- Q92719250 P2860 Q34419615 @default.
- Q92719250 P2860 Q34529981 @default.
- Q92719250 P2860 Q34533371 @default.
- Q92719250 P2860 Q34533379 @default.
- Q92719250 P2860 Q35760130 @default.
- Q92719250 P2860 Q48268762 @default.
- Q92719250 P2860 Q50094018 @default.
- Q92719250 P2860 Q53131122 @default.
- Q92719250 P2860 Q54114604 @default.
- Q92719250 P2860 Q56957641 @default.
- Q92719250 P2860 Q58107102 @default.
- Q92719250 P2860 Q89124309 @default.
- Q92719250 P2860 Q91737657 @default.
- Q92719250 P304 "1319-1327" @default.
- Q92719250 P31 Q13442814 @default.
- Q92719250 P356 "10.1002/CPT.1543" @default.
- Q92719250 P433 "6" @default.
- Q92719250 P478 "106" @default.
- Q92719250 P50 Q117258487 @default.
- Q92719250 P50 Q117258490 @default.
- Q92719250 P50 Q60785132 @default.
- Q92719250 P50 Q86910530 @default.
- Q92719250 P50 Q89971099 @default.
- Q92719250 P577 "2019-08-23T00:00:00Z" @default.
- Q92719250 P698 "31194885" @default.
- Q92719250 P921 Q187255 @default.
- Q92719250 P921 Q42824440 @default.
- Q92719250 P921 Q42824827 @default.
- Q92719250 P932 "6896251" @default.